JNJ-55308942

JNJ-55308942
Clinical data
Trade names	Zanvipixant
Legal status
Legal status	Investigational New Drug;
Identifiers
	IUPAC name (S)-(3-fluoro-2-(trifluoromethyl)pyridin-4-yl)(1-(5-fluoropyrimidin-2-yl)-6-methyl-6,7-dihydro-1H-[1,2,3]triazolo[4,5-c]pyridin-5(4H)-yl)methanone;
CAS Number	2166558-11-6 ;
PubChem CID	90408860;
DrugBank	DB19110;
ChemSpider	76771276;
UNII	B7YN3CQ7S7;
ChEMBL	ChEMBL3914857;
Chemical and physical data
Formula	C17H12F5N7O
Molar mass	425.323 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C[C@H]1CC2=C(CN1C(=O)C3=C(C(=NC=C3)C(F)(F)F)F)N=NN2C4=NC=C(C=N4)F;
	InChI InChI=1S/C17H12F5N7O/c1-8-4-12-11(26-27-29(12)16-24-5-9(18)6-25-16)7-28(8)15(30)10-2-3-23-14(13(10)19)17(20,21)22/h2-3,5-6,8H,4,7H2,1H3/t8-/m0/s1; Key:LMDWZBQISRTEBH-QMMMGPOBSA-N;

JNJ-55308942 is an investigational drug that works as a P2X7 antagonist with a downstream effect of reducing interleukin-1β release.^[1]^[2]^[3] It is developed by Janssen Pharmaceuticals for bipolar depression.^[4]